Brief: Hyloris Pharmaceuticals: Revision Of 2022, H1 2023 Financial Statements Following Correction Of Non-Cash Error

Hyloris Pharmaceuticals SA

14/03/2024 06:26

March 14 (Reuters) - Hyloris Pharmaceuticals SA
 HYL.BR :
    * COMMUNICATION AT THE REQUEST OF THE FSMA ON THE
TRANSACTIONS
WITH QLINIQ
    * REVISION OF 2022 AND HALF-YEAR OF 2023 (HY 2023) FINANCIAL
STATEMENTS FOLLOWING A CORRECTION OF A NON-CASH ERROR IN
ACCOUNTING TREATMENT OF TRANSACTIONS WITH QLINIQ ANNOUNCED ON 20
JANUARY 2023
    * HY-088 AND HY-038 CONSIDERED AS A NON-MONETARY EXCHANGE
UNDER
IAS 38.45 IN 2023
    * NO IMPACT ON CASH FLOW AND CASH POSITION
    * IT IS EXPECTED THAT HYLORIS WILL SUBMIT HY-088 FOR
REGISTRATION
IN COURSE OF 2025
    * TRANSACTION PRICE OF EUR 1.2 MILLION (INCLUDING EUR 200
THOUSAND
DESIGNATED AS PREPAID EXPENSES), WAS PAID BY HYLORIS ON 13
FEBRUARY 2023

Source text for Eikon:  ID:nGNE8THHVJ 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))